The term 'trans-splicing' encompasses several platform technologies that combine two RNA or protein molecules to generate a new, chimeric product. RNA trans-splicing reprograms the sequences of endogenous messenger mRNA or pre-mRNA, converting them to a new, desired gene product. Trans-splicing has broad applications, depending on the nature of the sequences that are inserted or trans-spliced to the defined target. Trans-splicing RNA therapy offers significant advantages over conventional gene therapy: expression of the trans-spliced sequence is controlled by the endogenous regulation of the target pre-mRNA; reduction or elimination of undesirable ectopic expression; the ability to use smaller constructs that transsplice only a portion of the gene to be replaced; and the conversion of dominant-negative mutations to wild-type gene products. Gene Therapy (2005) 
RNA therapy by trans-splicing
Most 'traditional' gene therapy strategies add the function of a full-length gene to a population of target cells while endogenous gene expression continues on in parallel. Delivery and regulated expression of the transgene are important considerations in many therapeutic applications to minimize undesirable ectopic gene expression in the wrong place, time, or quantity. In trans-splicing-based RNA therapeutics, a well-defined endogenously expressed target pre-mRNA is cut and a new sequence from a trans-splicing molecule is inserted or trans-spliced into the 3 0 , 5 0 , or internal sequence of the target to generate a new gene product ( Figure 1) . Expression of the trans-spliced gene is regulated by the control elements of the target gene. Undesired gene expression due to unintended delivery or misregulation is minimized as trans-splicing should only occur in those cells expressing the target pre-mRNA. In addition, transsplicing RNA therapy offers several other advantages over conventional gene therapy including the ability to use small constructs that trans-splice just a portion of the gene and the conversion of dominant-negative mutations to wild-type gene products. The two most commonly studied trans-splicing methodologies are spliceosomemediated RNA trans-splicing (SMaRTt) and ribozymemediated trans-splicing.
In brief Progress
Spliceosome-mediated RNA trans-splicing (SMaRTt) can reprogram the 5 0 , 3 0 or internal coding sequences of a targeted transcript. The therapeutic potential of SMaRTt has been demonstrated in vivo in different systems. Trans-splicing confers the endogenous regulation of the targeted transcript on the sequence that is transspliced. Trans-splicing is a tool for molecular imaging. Improvements in ribozyme mediated trans-splicing have been demonstrated in vitro. New technologies for trans-splicing RNA and protein are being developed. High-capacity screens to identify more efficient transsplicing molecules have been developed.
Prospects
Development and clinical testing of RNA transsplicing therapeutics. High-capacity screens will see wider application to improve the specificity and efficiency of trans-splicing in the complex environment of human cells. Understanding of the naturally occurring transsplicing process may improve the design of new trans-splicing molecules.
Spliceosome-mediated RNA trans-splicing (SMaRTt) can reprogram the 5 0 , 3 0 or internal coding sequences of a targeted transcript Eukaryotic post-transcriptional processing of pre-mRNA normally includes 5 0 capping, 3 0 polyadenylation, and cis-splicing reactions. At least 74% of multiexon human genes are alternatively spliced. 1, 2 Pre-mRNA splicing is carried out in the cell nucleus by spliceosomes, which are abundant and adaptable to recognize splice sites that may be several hundred thousand nucleotides apart. Thousands of splicing events are occurring at any one time in each human cell nucleus.
The complex of ribonucleoproteins and proteins that recognize splice sites and assemble to form each spliceosome are flexible and can catalyze splicing reactions between two independent pre-mRNAs, that is, trans-splicing. Spliceosomes can participate in two forms of trans-splicing. The first, spliced leader (SL) trans-splicing, occurs in trypanosomes, flatworms and plant mitochondria. SL trans-splicing requires the presence of an SL-RNA, which has a structure similar to one of the components of the spliceosome, U1 snRNA. The SL-RNA is spliced onto the 5 0 end of transcripts in these organisms ( Figure 2) . A second form of trans-splicing has been reported in higher eukaryotes. Spliceosomes mediate trans-splicing between 5 0 and 3 0 splice sites that are present on two individual pre-mRNAs. Spliceosomemediated RNA trans-splicing is a naturally occurring, albeit rare, process. The initial reports documented natural trans-splicing between transcripts of the same gene (homotypic) as well as trans-splicing between different genes (intergenic). 3 Further evidence of natural trans-splicing has recently been reported between two copies of a human estrogen receptor gene, 4 between different human cytochrome oxidase transcripts encoded on opposite strands, 5 and between endogenous cell and highly expressed adenoviral genes. 6 Analysis of various genetic databases have revealed a number of chimeric transcripts. Two of these, representing B0.01% of the Reference Sequence (RefSeq) collection (http://www. ncbi.nlm.nih.gov/RefSeq/) database may have been produced by trans-splicing. 7 These observations suggest that natural spliceosome-mediated trans-splicing is a rare event. The biological function associated with these naturally trans-spliced transcripts is unknown. 8 Since the spliceosome is assembled from parts which independently recognize 5 0 and 3 0 splice site sequences, more than 10 years ago one of us (LGM) proposed a series of RNAs designed to trans-splice with a selected endogenous target pre-mRNA. These pre-trans-splicing RNA molecules (PTMs) are comprised of three elements: a binding domain (BD) complementary to a chosen target 
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LG Mitchell and GJ McGarrity pre-mRNA, an unpaired splice site and a coding domaincontaining sequences to be trans-spliced into the target (Figure 3a ). Investigators at Intronn along with an expanding group of collaborators and other investigators have established that spliceosome-mediated RNA transsplicing (SMaRTt) can reprogram targeted pre-mRNAs in nuclear extracts, cells, and animal models with increasing efficiencies. PTMs can trans-splice 60% of endogenous human papilloma virus (HPV) target premRNAs in cultured cells from cervical cancers and have restored up to 22% of normal protein function in a cystic fibrosis xenograft model, a level which could provide therapeutic benefit in the treatment of a significant number of diseases. 9 SMaRTt has generated trans-splicing efficiencies up to 75% in cells cotransfected to express high levels of two RNAs designed to trans-splice with each other. 10 The first PTMs contained only 3 0 splice sites and, like trans-splicing ribozymes, reprogramed the 3 0 end of the target pre-mRNA (Figure 1a) . In contrast to ribozymes, SMaRTt offers a broader range of trans-splicing reactions since PTMs can reprogram the 5 0 region or internal sequences of target transcripts in cells (Figure 1b and c) . To prevent direct PTM expression, 3 0 exon replacement PTMs should be constructed without transcription start codons, 5 0 PTMs without polyadenylation signals, and double trans-splicing PTMs should lack both these sequence elements.
Most of our studies have focused on 3 0 exon replacement. However, we have also demonstrated that PTMs can trans-splice the 5 0 region of a transcript by replacing the 1.9 kb sequence coding for exons 1-10 of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene.
11 PTM plasmids were constructed to express a BD to intron 10 along with a 5 0 splice site and the coding sequences of CFTR exons 1-10. These were cotransfected in cultured human cells along with target plasmids that expressed CFTR DF508 exon 10, a mini-intron 10, and exons 11-24. Full-length trans-spliced CFTR mRNAs (B6% of cis-spliced target) and functional Cl À ion channels were generated. Double trans-splicing PTMs ( Figure 1c) containing two BDs and a 3 0 and a 5 0 splice site have also been demonstrated, producing low levels of doubly trans-spliced target RNA, protein, and functional activity (unpublished data).
Among other factors, the concentrations of the premRNA target and the PTM affect the rate of transsplicing. These concentrations can be maximized by cotransfection of DNA constructs that express high levels of the trans-splicing partners. A cotransfection strategy was employed to increase the levels of trans-spliced RNA in vivo in our original publication on SMaRTt. Pergolizzi et al 12 have used this approach to codeliver two plasmids that express high levels of 3 0 and 5 0 PTMs that hybridized and trans-spliced two halves of the coding sequence of a-cobra toxin to each other. Mice that received X7.5 mg of both PTM plasmids intravenously produced a-cobra toxin and died within 6 h. Delivery of two or more constructs designed to trans-splice with each other could be used to assemble large sequences that exceed the package limits of a single gene transfer vector, or to bypass problems associated with the production of toxin gene delivery vectors in packaging cells. Expression of each construct could be controlled by a different promoter to enhance specificity. However, unless at least one of the constructs also trans-spliced with a host cell transcript, the link to endogenous regulation provided by trans-splicing would be lost.
The therapeutic potential of SMaRTt has been demonstrated in vivo
Restoration of function and correction of phenotype in animal models and cell lines are important components in preclinical development. In a cystic fibrosis (CF) model, Liu et al 9 reported that PTMs delivered by adenoviral vectors could correct transepithelial cyclic AMP-sensitive short-circuit current in patient-derived DF508 homozygous epithelia to 16% of that observed in normal human bronchial epithelia. Using a human CF bronchial-mouse-xenograft model, partial correction of the CFTR-mediated Cl À permeability was achieved, generating 22% of the levels seen in non-CF xenografts. In this study, the PTM targeted intron 9 and replaced any mutation within the coding sequence of exons 10-24, a region of 3.2 kb. These levels of functional repair exceed the 8-10% level of normal CFTR activity considered to be sufficient to alter the disease phenotype. The first correction of a knock out (KO) animal by trans-splicing was achieved by Chao et al 13 using a hemophilia A mouse model with an insertion in exon 16 of the mouse factor VIII gene that eliminates all factor VIII activity. A PTM designed to base-pair with intron 15 and trans- 
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LG Mitchell and GJ McGarrity splice the coding sequence of exons 16-26 was delivered i.v. by plasmid or adenovirus to factor VIII KO mice. Over the 8-week study period, plasma levels of factor VIII reached a mean of 108.5 mU/ml, which is twice the plasma level of factor VIII present in patients with the mild form of hemophilia A. In all, 80% of PTMtreated mice survived a tail-clip hemostatic challenge, while none of the naïve or mock-injected animals survived.
PTMs have been delivered in vivo using a wide range of vectors including naked or complexed plasmids, adenovirus, retrovirus, lentivirus, and adeno-associated virus (AAV). We have also delivered PTMs as RNA molecules. The rate of trans-splicing is proportional to the concentrations of the target pre-mRNA and PTM. PTM levels generally follow the expected stability and expression profile of the chosen delivery system. Following portal vein delivery of PTMs by naked plasmid, factor VIII levels reached 13% of normal at 48-72 h and declined to baseline by day 7. The same factor VIII-PTM delivered by recombinant adenovirus produced 10.8% of normal levels of factor VIII at 3 weeks, activity was detected up to 8 weeks after injection. 13 AAV vectors have several attractive features, including a favorable safety profile; however, they have a DNA-packaging limit of o5 kb.
14 Even without the sequence elements necessary to control expression, the cDNA encoding many clinically relevant genes are too large to be delivered by AAV. Trans-splicing may be employed as a strategy to circumvent the need to package the full-length coding sequence of genes to treat diseases such as hemophilia A (factor VIII, 7-9 kb), muscular dystrophy (dystrophin, 11 kb), or various forms of epidermolysis bullosa (type VII collagen, 9.2 kb; plectin, 14.8 kb) along with appropriate regulatory elements. [15] [16] [17] The PTMs that repair CFTR or factor VIII have also been delivered by AAV vectors, generating 0 and 3 0 splice sites at the respective ends of each intron are not labeled. In the absence of a PTM, the pre-mRNA is cis-spliced to generate a mutant mRNA, which is exported to the cytoplasm, where it can be trans-spliced by two other approaches. Reaction B shows a ribozyme base pairing with the mutant mRNA through an internal guide sequence domain that incorporates the catalytic core of a group I intron. The ribozyme itself catalyzes trans-splicing between the 3 0 exons of the ribozyme and the 5 0 region of target mRNA. In reaction C, a delivered RNA forms a specific bulge-helix-bulge structure with the target mRNA, generating the substrate for a second delivered component, an endoribonuclease, which cleaves the BHB-mRNA complex. Trans-splicing is completed by an as yet, unidentified endogenous ligase.
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Trans-splicing confers the endogenous regulation of the targeted transcript on the sequence that is trans-spliced
There are several reports on the adverse effects of undesirable ectopic gene expression, including CFTR. 19 Tahara et al 20 employed SMaRTt to recapitulate endogenous expression while producing CD40 ligand (CD40L) in a KO model of this X-linked immunodeficiency. A previous study found that CD40L-KO mice developed T-lymphoproliferative disease within 9 months of receiving bone marrow cells transduced ex vivo with a retrovirus that expressed full-length CD40L gene. Undesired ectopic expression of CD40L has been shown to cause T-cell lymphoproliferation or lymphomas. To avoid this adverse outcome, RNA trans-splicing was chosen to link expression of the repaired mRNA to that of the endogenous CD40L gene. Since the PTM delivered only a portion of the CD40L gene, undesirable ectopic expression of full-length CD40L was unlikely. Treated mice produced both IgM and IgG in response to antigen stimulation and markedly attenuated Pneumocystis carinii proliferation following respiratory challenge. Mice evaluated 3-12 months post-treatment displayed no evidence of lymphoproliferation, demonstrating the safety advantage conferred by trans-splicing.
Trans-splicing is a tool for molecular imaging
Trans-splicing technologies have a variety of applications, depending on the sequence trans-spliced into the target. Trans-spliced reporter genes may be used to follow the process of trans-splicing itself or to identify target gene expression within living cells. Numerous studies to develop ribozyme-or spliceosome-mediated RNA trans-splicing have used the repair of lacZ, green fluorescent protein or other reporter genes to quantify the efficiency of trans-splicing in cells. 17, 21, 22 We recently demonstrated in vivo proof of concept of SMaRTt molecular imaging to visualize endogenous gene expression using a split-reporter gene system. 23 Mice were injected with 1 Â 10 6 N2a mouse neuroblastoma cells that contained a target plasmid expressing the 5 0 portion of Renilla luciferase followed by the E6-E7 region of the HPV, a sequence detected in virtually all cervical cancers. No significant bioluminescent activity was detected in these mice following intraveneous injection of the luciferase substrate. A PTM was constructed to transsplice to the E6-E7 region of HPV and insert the 3 0 portion of Renilla luciferase into the target pre-mRNA, generating the full-length coding sequence of luciferase. PTM expression plasmids were complexed with transferin-PEI and injected (50 mg) into the tail vein of test animals 4 or 24 h after target cell injection. Following injection of the luciferase substrate, optical images were generated by detecting luciferase activity in target cells located in subcutaneous tumors and deeper tissues, such as the liver. This was the first study to visualize real-time gene expression in live animals by RNA trans-splicing. It represents an important step towards the universal imaging of an endogenous pre-mRNA target, with potential applications in research and diagnostics. The coding domain of the PTM can be easily changed to encode a reporter more suitable for molecular imaging in humans by PET, or to produce a protein that acts therapeutically.
Improvements in ribozyme-mediated trans-splicing in vitro have been made
Trans-splicing ribozymes were originally derived from Group I self-splicing introns by Sullenger and Cech (Figure 3b) . Trans-splicing ribozymes include a complementary internal guide sequence that base-pairs with the target RNA, a ribozyme domain, and a 3 0 terminal exon to be trans-spliced. The binding catalyzes the cleavage of the target and ligation of the ribozyme-encoded 3 0 exon. They do not require splicing or other factors and are active in relatively simple buffered solutions containing guanosine or in Escherichia coli. Such conditions have been utilized to map the most accessible and reactive ribozyme sites in a target mRNA. [24] [25] [26] [27] Lead ribozymes targeting accessible mRNA regions are chosen from ribozyme libraries that contain randomized internal guide sequences. Selected ribozymes are individually tested for efficiency and specificity in the more complex environment of human cells. However, demonstration of therapeutic potential by trans-splicing ribozymes in animal models and clinical application will likely require improvement in the efficiency and specificity of the reaction in vivo. 28 Shin et al 21 recently developed a ribozyme that repairs p53 mRNA by trans-splicing at a site upstream of the AUG start codon. This ribozyme is capable of repairing any mutation in the coding sequence of p53. The repaired transcripts produced functional p53 protein in a human ovarian cancer cell line, demonstrated by luciferase expression driven by a p53-responsive promoter and an increase in apoptotic cells. This study was the first demonstration of protein activity generated by the translation of a ribozyme-repaired endogenous mRNA in human cells, a significant early milestone in the development of trans-splicing ribozymes for therapeutic application. Loss of p16 function is the second most common gene alteration in human tumors. A transsplicing strategy to repair mutations in the coding sequence of p16 in a pancreatic cancer cell line has been demonstrated. 29 Although the amount of protein detected was low, the cells transfected with this ribozyme construct grew slower than controls over an 8-day period. These reports highlight the importance of regulating the expression of p53 and p16 and the link to endogenous regulation conferred by trans-splicing. Most mutant p53 proteins exert a dominant-negative effect. Each trans-spliced mRNA lowers the production of mutant p53 while simultaneously increasing levels of wild-type p53 protein.
Trans-splicing ribozymes have also found application in targeting infectious diseases, such as hepatitis caused by the hepatitis C virus (HCV). HCV has an RNA genome without introns. As ribozymes function in the cytoplasm, they can be used to reprogram such targets. Ryu and Lee 24 used an extended internal guide sequence to improve specificity in targeting a conserved region of the HCV internal ribosome entry site (IRES). Transsplicing removed two in frame upstream stop codons in the ribozyme, enabling the viral IRES to drive the expression of trans-spliced luciferase or diphtheria toxin Gene therapy progress and prospects LG Mitchell and GJ McGarrity subunit A sequences. 22 The combination of these two features improved the specificity of toxin expression in human cells cotransfected with target and ribozyme expression plasmids.
Rogers et al 30 repaired mRNA expressed from a cotransfected or stably integrated mutant canine skeletal muscle chloride channel gene in HEK-293 cells using a ribozyme that trans-spliced 4 kb of the 3 0 exon. Quantitative RT-PCR revealed a low repair efficiency (1.2%) and patch-clamp analysis of individual cells produced a broad range of functional restoration. In all, 18% of treated cells exhibited some improvement in electrophysiological activity and a few had complete restoration of wild-type function. Several possible explanations for this variability were offered, including heterogeneity of the cell cycle, variable delivery and expression of the ribozyme, and colocalization target and ribozyme.
Sullenger et al 31 have reported progress towards improving ribozyme activity in mammalian cells when expressed by pol II promoters, circumventing the difficulty they encountered in expressing long ribozymes from pol III promoters. Trans-splicing efficiency was increased by adding five or more nucleotides to create an external guide sequence and four to six nucleotides of complementarity to form a p10 interaction loop between the 5 0 end of the ribozyme and the beginning of its 3 0 exon. Neither of these additions are required for transsplicing activity when mammalian cells are transfected with in vitro transcribed ribozymes. These changes boosted the level of trans-splicing over their previous results, repairing B10% of sickle b-globin mRNAs in 293 cells cotransfected with both target and pol II ribozyme expression plasmids. These new studies document steady progress towards improving the efficiency and specificity of trans-splicing ribozymes. In vivo delivery and demonstration of therapeutic potential in animal models are important milestones that remain to be achieved by trans-splicing ribozymes. 28 Currently, it is unclear why trans-splicing ribozyme efficiency is insufficient to restore function in animal models, although ribozyme concentration, variable RNA folding, and the interaction of the ribozyme with accessible target sites have been raised as possiblities. 29 Other technologies for trans-splicing RNA and protein are being developed A third form of RNA trans-splicing has recently been described. 32 This new trans-splicing system coexpressed the tRNA endonuclease from the archaebacterium Methanococcus jannaschii in mouse cells along with an engineered targeting RNA. Upon encountering a complementary target mRNA, the target and targeting RNAs form a specific bulge-helix-bulge structure that is specifically recognized and cleaved by the endonuclease 28, 32 ( Figure 3b ). The cut RNAs are subsequently joined by an as yet unidentified endogenous ligase.
Proteins can also be engineered to trans-splice into each other. A variety of lower organisms express proteins which undergo cis-splicing-mediated by inteins. An intein is a protein sequence that can splice itself out of the precursor protein in which it is embedded. Like ribozymes, inteins do not naturally mediate transsplicing. Inteins can be split into N-and C-terminal fragments. Split inteins may be incorporated into different proteins or peptides to perform protein transsplicing, joining two separate precursors into a new chimeric molecule. Intein mediated trans-splicing has been demonstrated in mammalian cells. (Figure 4 ) Kinsella et al 33 have engineered a retroviral library coding for randomized 4-mer peptides linked by split inteins to generate a library of cyclic polypeptides in human cells. These peptides were subsequently screened for ability to block the IL-4 signaling pathway in human B cells. Disruption of this pathway is a potential therapeutic approach to lower IgE levels in conditions such as allergy and asthma. Li et al 34 have also adapted trans-splicing inteins to overcome the size limitations of AAV-based gene delivery, splitting the 6.3 kb Beckerform dystrophin cDNA into equal portions, then adding an N-or C-terminal intein coding fragment. These two half genes were separately packaged into AAV vectors. Cotransduction of these two vectors produced fulllength Becker form dystrophin protein in the muscle of dystrophic mice that was correctly localized in myofibers and prevented central nucleation pathology. Intein-based 
High-capacity screens have been developed
The design requirements for a trans-splicing RNA to efficiently and specifically reprogram a defined premRNA target are not fully understood. Improvements in specificity and efficiency were initially accomplished by rational design, construction and testing of candidate trans-splicing molecules one at a time. This approach is untenable when considering the vast numbers of potential designs. A better method to identify optimal trans-splicing constructs would be able to rapidly select the best performers from a large pool of variants in human cells.
Ayre et al 36 described a yeast-based screen to identify efficient ribozymes by trans-splicing a transcription factor that conferred a growth advantage. In that study, the library consisted of 13 mixed ribozymes. Hasegawa et al 37 have developed a fluorescent reporter system that they propose could be adapted to screen libraries based on trans-splicing activity in single mammalian cells, demonstrating the repair of a split b-lactamase gene using one active ribozyme in human cells by fluorescence microscopy and FACS. However, analysis of cells transfected with the single active ribozyme construct revealed a wide range of fluorescence (43 logs). This is a significant level of heterogeneity, which should be reduced before screening libraries with large populations of variant ribozymes.
We have developed a functional high-capacity screen for SMaRTt that can select lead PTMs from initial libraries of 410 6 BD sequence combinations in approximately 2 months. Libraries complementary to seven premRNA targets have been generated by sonicating selected regions of a target pre-mRNA, such as the E6-E7 region of HPV or intron 14 of factor VIII. These randomized fragments were cloned into the BD region of PTM expression plasmids that also contained a 3 0 splice site and the 3 0 half of green fluorescent protein (GFP). PTM libraries were clonally delivered to assay cells that expressed a pre-mRNA comprising the 5 0 half of GFP and the target intron. Successful trans-splicing of a candidate BD to the target sequence produces green fluorescence, which is assayed by FACS ( Figure 5 ). The intensity of fluorescence correlates with the efficiency of trans-splicing. The PTMs selected from the screen typically demonstrated five-to 10-fold greater efficiency in trans-splicing to target than the best rationally designed PTMs. Figure 5 High-capacity PTM screen. A randomized PTM library is constructed by sonicating a chosen target intron, then cloning the resulting fragments into the binding domain region of PTM expression plasmids. These PTMs are capable of trans-splicing the 3 0 portion of green fluorescent protein (GFP). The PTM library is transfected into target cells that express the 5 0 portion of GFP and the chosen target intron. Cells containing PTMs that most efficiently trans-splice into the target generate the highest levels of GFP and can be selected by FACS. The plasmids encoding optimal trans-splicing PTMs can be recovered by DNA extraction or PCR from the collected cells.
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Future prospects
The ultimate test for the utility of RNA therapeutics will be determined by human clinical trials. We anticipate commencing clinical trials for SmaRTt in 2006. We currently have therapeutic programs for hemophilia A, alpha 1-antitrypsin deficiency and dyslipidemia. The goal in dyslipidemia is to increase blood levels of ApoA1 and subsequently high-density lipoprotein by transsplicing to highly abundant transcripts such as albumin pre-mRNA. While SMaRTt is attractive to treat genetic diseases, it also has applications for acquired diseases. For example, a single trans-splicing event could be sufficient to kill one or many cells in a solid tumor if a uniquely expressed cancer gene was reprogramed to express a potent toxin with a bystander effect.
Improvements in high-capacity screens and in the understanding of trans-splicing should accelerate the creation of optimal trans-splicing constructs. In turn, those parameters identified with optimal trans-splicing, in combination with computer modeling of target molecules and the trans-splicing reaction could expedite the design of new PTMs. The recent work on both ribozymes and PTMs have demonstrated that specificity can be improved by modifying the target recognition sequences and in the case of ribozymes, by adding additional base-pairing sequences to the active site. Improvements in specificity may also correlate with increased efficiency.
The pursuit of the therapeutic applications of RNA trans-splicing might be significantly accelerated by studies on the naturally occurring process of transsplicing. This may lead to a better understanding of the functional genome and the role trans-splicing plays in normal gene expression and in disease.
